GlassScriptPhysician profile
Moustafa A Moustafa
NPI 1356431449
$615,928.23
in general payments reported to CMS, 2019-2025
38 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232K · 2020: $98K · 2021: $81K · 2022: $166K · 2023: $29K · 2024: $7,979 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,475 · Consulting Fee: $6,498 · Food and Beverage: $4,230 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $19,433.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,475.00 |
| Consulting Fee | $6,498.00 |
| Food and Beverage | $4,230.03 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $540,109.67 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $23,427.93 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $23,024.12 | 2019-2025 | Parsabiv, Tavneos, Aranesp |
| Glaxosmithkline, LLC. | $8,224.97 | 2023 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $6,892.86 | 2019-2024 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $5,434.21 | 2020-2023 | Veltassa |
| Calliditas Therapeutics US INC. | $2,043.68 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $1,469.48 | 2023-2025 | |
| Novo Nordisk As | $1,281.36 | 2019 | |
| Astrazeneca Uk Limited | $1,063.76 | 2019 | |
| Aurinia Pharma U.S., INC. | $565.31 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $450.87 | 2020-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $297.75 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $261.83 | 2019 | |
| Opko Pharmaceuticals, LLC | $203.69 | 2019-2024 | Rayaldee |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $167.78 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $162.17 | 2020-2025 | Terlivaz, Acthar |
| Renalytix Ai, INC. | $116.36 | 2022-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.07 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $102.68 | 2023-2025 | |
| Corcept Therapeutics | $95.85 | 2023-2025 | Korlym |
| Nxstage Medical, INC. | $79.57 | 2019-2020 | |
| Scpharmaceuticals INC. | $61.40 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $51.40 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $40.14 | 2021-2023 | Onpattro |
| Alexion Pharmaceuticals, INC. | $37.65 | 2024 | Ultomiris |
| Genzyme Corporation | $37.07 | 2020-2021 | |
| Horizon Therapeutics Plc | $33.76 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $30.33 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $27.04 | 2023 | Crysvita |
| Daiichi Sankyo INC. | $20.47 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moustafa Moustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.